menu
    • menu

    Company profile for Laboratorium Ofichem B.V

    Ofichem-PSE
    News
    Ofichem Acquires Swedish Site from Meribel Pharma Solutions

    29 Jul 2025

    // PRESS RELEASE

    Ofichem Group to Acquire Avivia

    09 Jul 2025

    // PRESS RELEASE

    Ofichem will support IPCEI Med4Cure project as associated partner

    23 Sep 2024

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Ofichem RM

    Contact Supplier

    Website

    CPhI WW Frankfurt

    Booth #11.0A89

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.youtube.com/embed/E5mufcVReD4

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Laboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.

    Related CompaniesRelated Companies

    About

    Laboratorium Ofichem is a GMP-certified and FDA-approved API manufacturer with state-of-the-art development and production facilities in the Netherlands. We develop and manufacture small molecule APIs in a cost-effective, robust, and compliant way. We have our own portfolio of generic APIs, but we also operate as a CDMO for a wide range of customers. We are a stable family-owned business and with nearly 50 years of experience we have a long history of regulatory compliance and a strong reputation for reliability and quality.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Laboratorium Ofichem B.VNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Heembadweg 5, 9561 CZ, Ter Apel
    Telephone
    Telephone
    +31 0599583433
    Client Email
    Email
    info@labofichem.com
    Client Website
    Website
    https://ofichem.com/nl/business-units/lab-ofichem
    Linkedin
    Linkedin
    https://nl.linkedin.com/company/laboratorium-ofichem-b.v.
    youtube
    YouTube
    http://www.youtube.com/@ofichemgroup
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI WW Frankfurt

    Booth #11.0A89

    envelop Contact Supplier

    CPhI WW Frankfurt

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/laboratorium-ofichem-bv-party-content-63881.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/laboratorium-ofichem-bv-party-content-69000.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/laboratorium-ofichem-bv-party-content-29767.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3917

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions

    #PharmaFlow by PHARMACOMPASS
    19 Dec 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Ofichem Acquires Swedish Site from Meribel Pharma Solutions
    Ofichem Acquires Swedish Site from Meribel Pharma Solutions

    29 Jul 2025

    // PRESS RELEASE

    https://ofichem.com/nl/nieuws/__temp_dcbszhbmsgmnnkxoelimswcxabcvvankfjym

    PRESS RELEASE
    29 Jul 2025
    Share Share
    Ofichem Group to Acquire Avivia
    Ofichem Group to Acquire Avivia

    09 Jul 2025

    // PRESS RELEASE

    https://ofichem.com/nl/nieuws/ofichem-acquires-avivia-b-v-to-expand-formulation-development-capabilities

    PRESS RELEASE
    09 Jul 2025
    Share Share
    Ofichem will support IPCEI Med4Cure project as associated partner
    Ofichem will support IPCEI Med4Cure project as associated partner

    23 Sep 2024

    // PRESS RELEASE

    https://ofichem.com/en/news/ofichem-will-support-the-ipcei-med4cure-project-as-associated-partner

    PRESS RELEASE
    23 Sep 2024
    Share Share
    Drug manufacturer InnoGenerics acquired.
    Drug manufacturer InnoGenerics acquired.

    23 Jan 2023

    // PRESS RELEASE

    https://ofichem.com/en/news/medicijnfabrikant-innogenerics-overgenomen?l=en

    PRESS RELEASE
    23 Jan 2023
    Share Share
    Ofichem Group is going to produce medicines: 'We want to go from powders to pills'
    Ofichem Group is going to produce medicines: 'We want to go from powders to pills'

    08 Oct 2022

    // RTVNOORD

    https://www.rtvnoord.nl/nieuws/964265/ofichem-group-gaat-medicijnen-produceren-we-willen-van-poeders-naar-pillen

    RTVNOORD
    08 Oct 2022
    Share Share
    Ofidit Enters Strategic Pharmaceutical Audit Partnership with Rephine
    Ofidit Enters Strategic Pharmaceutical Audit Partnership with Rephine

    16 May 2022

    // PRESS RELEASE

    https://ofichem.com/nl/nieuws/partners-in-business

    PRESS RELEASE
    16 May 2022
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    API Development

    read-more
    read-more

    01

    CDMO FOR APIs

    Netherlands
    Contact Supplier
    arrow
    CPhI WW Frankfurt
    Booth #11.0A89
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLaboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.

    Pharma Service : API & Drug Product Development

    Laboratorium Ofichem B.V

    With over 45 years of experience in the production of niche APIs, Ofichem develops, produces & distributes APIs worldwide. It can safely & simultaneously develop & produce a broad range of APIs for the human & veterinary pharmaceutical markets.

    arrow

    Category : API Development

    Sub Category : Overview

    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLaboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.

    Pharma Service : API & Drug Product Development

    CDMO FOR APIs

    With over 45 years of experience in the production of niche APIs, Ofichem develops, produces & distributes APIs worldwide. It can safely & simultaneously develop & produce a broad range of APIs for the human & veterinary pharmaceutical markets.

    arrow
    Ofichem CDMO for APIs

    Service
    Web Link

    Capabilities
    #ServicesBio

    Market
    Place

    02

    SMALL SCALE BATCH FOR APIs

    Netherlands
    Contact Supplier
    arrow
    CPhI WW Frankfurt
    Booth #11.0A89
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLaboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.

    Pharma Service : API & Drug Product Development

    Laboratorium Ofichem B.V

    Ofichem's thirteen API production facilities can be used for large-scale, medium-scale and small-scale production. It can safely and simultaneously produce a broad range of APIs for the human and veterinary pharmaceutical markets.

    arrow

    Category : API Development

    Sub Category : Small Scale Batch

    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLaboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.

    Pharma Service : API & Drug Product Development

    SMALL SCALE BATCH FOR APIs

    Ofichem's thirteen API production facilities can be used for large-scale, medium-scale and small-scale production. It can safely and simultaneously produce a broad range of APIs for the human and veterinary pharmaceutical markets.

    arrow
    Ofichem Small Scale Batch for APIs

    Service
    Web Link

    Capabilities
    #ServicesBio

    Market
    Place

    03

    API SCALE-UP

    Netherlands
    Contact Supplier
    arrow
    CPhI WW Frankfurt
    Booth #11.0A89
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLaboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.

    Pharma Service : API & Drug Product Development

    Laboratorium Ofichem B.V

    Ofichem is a CDMO that offers APIs from small (20L, 60L, 100L) to multi-MT scales (1500L, 4000L) to meet clients’ needs. Its cGMP manufacturing facility is involved in the production of small, medium, and large-scale APIs.

    arrow

    Category : API Development

    Sub Category : Scale-Up Capabilities

    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLaboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.

    Pharma Service : API & Drug Product Development

    API SCALE-UP

    Ofichem is a CDMO that offers APIs from small (20L, 60L, 100L) to multi-MT scales (1500L, 4000L) to meet clients’ needs. Its cGMP manufacturing facility is involved in the production of small, medium, and large-scale APIs.

    arrow
    Ofichem API Scale-Up

    Service
    Web Link

    Capabilities
    #ServicesBio

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Laboratorium Ofichem B.V full-view
    Development of High-Value/Low-Volume Niche-Complex APIs
    full-view
    Small Scale Batch
    full-view
    cGMP Contract Manufacturing of API
    full-view
    Two Kilo-Labs, Compliant to cGMP for Production
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    FDA

    read-more
    read-more

    01

    FDA Audited

    USA
    arrow
    CPhI WW Frankfurt
    Booth #11.0A89

    District Decision : No Action Indicated

    Inspection End Date : 2019-09-18

    Laboratorium Ofichem B.V

    City : Ter Apel

    State :

    Country/Area : Netherlands

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2019-09-18

    Ofichem Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    02

    FDA Audited

    USA
    arrow
    CPhI WW Frankfurt
    Booth #11.0A89

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2015-12-17

    Laboratorium Ofichem B.V

    City : Ter Apel

    State :

    Country/Area : Netherlands

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2015-12-17

    Ofichem Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    GDUFA

    read-more
    read-more

    01

    GDUFA fees paid

    USA
    arrow
    CPhI WW Frankfurt
    Booth #11.0A89
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLaboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.

    Paid in : 2025

    Laboratorium Ofichem B.V

    API Manufacturer : API MANUFACTURE

    FDF Manufacturer :

    Facility Name : Laboratorium Ofichem B.V.

    Business Address : Heembadweg 5 Ter Apel 9561 C...

    FEI Number : 1000286391

    Country : Netherlands

    Paid in : 2025

    Ofichem Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Contact Laboratorium Ofichem B.V and get a quotation

    Laboratorium Ofichem B.V is a supplier offers 39 products (APIs, Excipients or Intermediates).

    Find a price of Disodium Pamidronate Pentahydrate bulk with CEP, JDMF offered by Laboratorium Ofichem B.V

    Find a price of Histamine Dihydrochloride bulk with DMF, CEP offered by Laboratorium Ofichem B.V

    Find a price of Dimethyl Fumarate bulk with DMF offered by Laboratorium Ofichem B.V

    Find a price of Edetate Calcium Disodium bulk with DMF offered by Laboratorium Ofichem B.V

    Find a price of Histamine Dihydrochloride bulk with CEP offered by Laboratorium Ofichem B.V

    Find a price of Zinc Acetate Dihydrate bulk with JDMF offered by Laboratorium Ofichem B.V

    Find a price of 2-Deoxy-D-Glucose bulk offered by Laboratorium Ofichem B.V

    Find a price of 3-Hydroxybutanoate bulk offered by Laboratorium Ofichem B.V

    Find a price of Bupropion Hydrochloride bulk offered by Laboratorium Ofichem B.V

    Find a price of Calcium Monoethyl Fumarate bulk offered by Laboratorium Ofichem B.V

    Find a price of Colistin Sulfate bulk offered by Laboratorium Ofichem B.V

    Find a price of Dimethyl Fumarate bulk offered by Laboratorium Ofichem B.V

    Find a price of Dimethyltryptamine bulk offered by Laboratorium Ofichem B.V

    Find a price of Edetate Calcium Disodium bulk offered by Laboratorium Ofichem B.V

    Find a price of Formic Acid bulk offered by Laboratorium Ofichem B.V

    Find a price of Guanabenz bulk offered by Laboratorium Ofichem B.V

    Find a price of Histamine Diphosphate Monohydrate bulk offered by Laboratorium Ofichem B.V

    Find a price of Ibandronate Sodium bulk offered by Laboratorium Ofichem B.V

    Find a price of Magnesium Monoethylfumarate bulk offered by Laboratorium Ofichem B.V

    Find a price of Mannitol API bulk offered by Laboratorium Ofichem B.V

    Find a price of Methenamine Hippurate bulk offered by Laboratorium Ofichem B.V

    Find a price of Methenamine Mandelate bulk offered by Laboratorium Ofichem B.V

    Find a price of Naphazoline Hydrochloride bulk offered by Laboratorium Ofichem B.V

    Find a price of Oxalic Acid bulk offered by Laboratorium Ofichem B.V

    Find a price of Palmitoylethanolamide bulk offered by Laboratorium Ofichem B.V

    Find a price of Phenylacetyl Disulfide bulk offered by Laboratorium Ofichem B.V

    Find a price of Phthalylsulfathiazole bulk offered by Laboratorium Ofichem B.V

    Find a price of Potassium Bromide bulk offered by Laboratorium Ofichem B.V

    Find a price of Silver Nitrate bulk offered by Laboratorium Ofichem B.V

    Find a price of Sodium Benzoate bulk offered by Laboratorium Ofichem B.V

    Find a price of Sodium Phenylacetate bulk offered by Laboratorium Ofichem B.V

    Find a price of Sucrose API bulk offered by Laboratorium Ofichem B.V

    Find a price of Sulfadiazine bulk offered by Laboratorium Ofichem B.V

    Find a price of Sulfadimethoxine Sodium bulk offered by Laboratorium Ofichem B.V

    Find a price of Sulfamethazine Sodium bulk offered by Laboratorium Ofichem B.V

    Find a price of Sulfathiazole Sodium bulk offered by Laboratorium Ofichem B.V

    Find a price of Tetrahydrocannabinol bulk offered by Laboratorium Ofichem B.V

    Find a price of Trehalose Dihydrate API bulk offered by Laboratorium Ofichem B.V

    Find a price of Vitamin A bulk offered by Laboratorium Ofichem B.V

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search